This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Chemours (CC) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of -16.88% and 3.63%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights LyondellBasell, Chemours, Axalta Coating Systems and Ashland
by Zacks Equity Research
LyondellBasell, Chemours, Axalta Coating Systems and Ashland are included in this Analyst Blog.
4 Chemical Stocks Set to Pull Off a Beat This Earnings Season
by Anindya Barman
While softer demand in certain end markets is likely to be a drag, LyondellBasell (LYB), Chemours (CC), Axalta Coating Systems (AXTA) and Ashland (ASH) are likely to have benefited from cost and pricing actions.
Why Chemours (CC) Could Beat Earnings Estimates Again
by Zacks Equity Research
Chemours (CC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Earnings Preview: FMC (FMC) Q3 Earnings Expected to Decline
by Zacks Equity Research
FMC (FMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Chemours (CC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How to Find Strong Basic Materials Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Are Options Traders Betting on a Big Move in Chemours (CC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Chemours (CC) stock based on the movements in the options market lately.
Here's Why You Should Hold Onto Chemours (CC) Stock For Now
by Zacks Equity Research
Chemours (CC) gains on strong execution, continued Opteon adoption and its efforts to reduce costs amid headwinds from demand weakness.
Chemours (CC) Benefits From Opteon Adoption Amid Demand Woes
by Zacks Equity Research
Although Chemours (CC) is being challenged by softer demand in certain businesses, it gains on continued Opteon adoption, strong execution and its cost-reduction and pricing actions.
Here's Why You Should Retain Chemours (CC) in Your Portfolio
by Zacks Equity Research
While Chemours (CC) is exposed to headwinds from demand softness in certain areas, it gains on continued Opteon adoption, strong execution and its cost-reduction and pricing actions.
Chemours (CC) Announces Development of New Specialty Fluid
by Zacks Equity Research
Chemours' (CC) introduction of Opteon 2P50 is a critical step in positioning the company to meet a growing challenge brought on by a new era of data transmission.
Cabot (CBT) Joins US Energy Department's Better Plants Program
by Zacks Equity Research
Cabot (CBT) believes that this engagement with the DOE will help the company boost its energy efficiency performance.
Chemours (CC) Q2 Earnings Beat, Titanium Technologies Hurt Sales
by Zacks Equity Research
Chemours' (CC) Titanium Technologies sales were hurt by lower volumes due to weaker demand in all regions in Q2.
Methanex (MEOH) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Methanex (MEOH) delivered earnings and revenue surprises of 9.09% and 4.26%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Huntsman (HUN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Huntsman (HUN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Titanium Technologies Unit Hurt Chemours (CC) Q2 Earnings?
by Zacks Equity Research
Slow demand recovery in the Titanium Technologies segment is expected to have weighed on Chemours' (CC) performance in the second quarter.
Earnings Preview: Chemours (CC) Q2 Earnings Expected to Decline
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemours (CC) Scales 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Chemours (CC) benefits from strong Opteon demand, effective execution, and its cost-reduction and pricing actions.
Chemours (CC) Stock Up 16% in 3 Months: What's Driving It?
by Zacks Equity Research
Chemours (CC) gains on healthy Opteon demand, strong execution and its cost-reduction and pricing actions.
Chemours (CC) Gains on Opteon Adoption Amid Demand Woes
by Zacks Equity Research
While Chemours (CC) is exposed to headwinds from demand softness in certain areas, it gains on continued Opteon adoption, strong execution and its cost-reduction and pricing actions.
Chemours (CC) to Divest Glycolic Acid Business to PureTech
by Zacks Equity Research
Chemours (CC) believes that its Glycolic Acid portfolio complements PureTech's growth strategy.
Strength Seen in Chemours (CC): Can Its 24.1% Jump Turn into More Strength?
by Zacks Equity Research
Chemours (CC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Here's Why You Should Hold Onto Chemours (CC) Stock for Now
by Zacks Equity Research
While Chemours (CC) is exposed to headwinds from demand weakness in certain businesses, it gains on healthy Opteon adoption and its pricing actions.
Chemours (CC) Extends Capacity to Meet Customers' Needs
by Zacks Equity Research
Chemours (CC) offers a portfolio of HFO-1336mzzZ-based products that are more environmentally friendly than non-HFO alternatives.